FluMist is a nasal spray manufactured by AstraZeneca that has been used to protect against influenza in the United States ...

The vaccine FluMist, manufactured by MedImmune, which was acquired by AstraZeneca in 2007, was first approved by the FDA in 2003 for individuals between five and 49 years of age. Its approval has ...

Recent health developments include the EU backing Novo Nordisk's Wegovy for obesity-related heart conditions, FDA approvals ...

A pill Novo acquired produced modest weight loss but raised safety questions. Elsewhere, Sanofi detailed the silver lining it found in a recent study and a heart drug developer’s shares surged.

AstraZeneca's FluMist influenza vaccine, which can be self-administered. Experts hope an option for at-home flu vaccination ...

The FDA Friday approved the flu vaccine that can be done at home and does not need to be administered by a health care provider.

The FDA is clearing the way for an at-home flu vaccines. A self-administered version of pharmaceutical giant AstraZeneca’s ...

The AstraZeneca PLC ADR AZN slumped 0.66% to $78.38 Friday, on what proved to be an all-around mixed trading session for the ...

AstraZeneca PLC AZN shares inched down 0.99% to £117.80 Friday, on what proved to be an all-around rough trading session for ...

Instead of four equal quarterly distributions, AstraZeneca insists on two payments per year, with a greater portion announced ...

JMP Securities has initiated coverage on BeiGene highlighting the Chinese biotech company as a 'unique investment opportunity.' The firm's leading drug, Brukinsa (zanubrutinib), is emerging in the ...

Approximately half of EGPA patients also have adult-onset severe eosinophilic asthma, or SEA, for which Fasenra is only the second biologic approved treatment. Fasenra is now approved as an add-on ...